Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Cetuximab Stories

2013-09-25 12:28:16

Increased Incidence and the Launches of Premium-Priced Agents Will Sustain Four Percent Annual Growth in the Turkish Market, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the colorectal cancer (CRC) market in Turkey will grow at an annual rate of four percent, reaching $90 million...

2013-09-23 13:13:29

Analysis of RTOG 0617 trial evaluates the impact of high-dose radiation therapy An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual...

2013-09-12 08:31:06

THOUSAND OAKS, Calif., Sept. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present new data from studies of marketed and pipeline products at the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress happening Sept. 27 to Oct. 1 in Amsterdam. "Amgen's continued focus on growth through innovation is highlighted by the data that we are presenting at the European Cancer Congress this year," said Sean E. Harper, M.D., executive vice president of Research and...

2013-07-26 11:16:52

Testing dropped once funding from pharmaceutical industry was discontinued Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar manner. More recently, the importance of pathologic subtype has been recognized. Data from several randomized trials demonstrate that epidermal growth factor (EGFR) mutation...

2013-07-02 08:26:58

Trial Adds Immunotherapy to Current Standard of Care Regimen SEATTLE, July 2, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. announced today the initiation of the ACTIVE8 clinical trial, a randomized, placebo-controlled, Phase 2 trial evaluating VTX-2337 in combination with a standard of care regimen, cetuximab, platinum and 5 Fluorouracil (5-FU), in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Logo:...

2013-06-26 12:31:40

A Drug's Label and Reimbursement Barriers are Factors that Impact Medical Oncologists' Sequential Prescribing of Targeted Agents, According to a New Report from Decision Resources BURLINGTON, Mass., June 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for metastatic colorectal (mCRC), a majority of surveyed oncologists most frequently prescribe a regimen containing...

2013-06-04 11:11:14

Correlation of protein phenotype brings researchers one step closer to personalized cancer treatment MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center. The study results, which compared MET protein expression with protein/gene expression of EMT markers and evaluated impact on...

2013-06-03 10:54:17

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET...

2013-06-03 08:27:28

Data Demonstrate Evidence of Indoximod's Safety and Anti-Tumor Activity When Used in Combination with Other Anti-Cancer Agents in Metastatic Solid Tumors AMES, Iowa, June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway. Indoximod was tested...

2013-05-30 13:48:47

In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC). Of all the patients in the US with lung cancer, the country's leading cause of cancer death, 75 to 80 percent of them have NSCLC, with 30 to 40 percent of those being considered locally advanced...